Is Celularity, Inc. overvalued or undervalued?

As of 14 August 2023, the valuation grade for Celularity, Inc. has moved from very attractive to risky, indicating a significant shift in its financial outlook. The company is currently assessed as overvalued, particularly given its troubling financial ratios. The P/E ratio is not applicable due to losses, while the Price to Book Value stands at 5.64, and the EV to EBITDA is at -2.98, reflecting negative earnings before interest, taxes, depreciation, and amortization.
In comparison with peers, Celularity's valuation appears unfavorable; for instance, PaySign, Inc. is categorized as very expensive with a P/E of 45.55, while FONAR Corp. is deemed attractive with a P/E of 8.12. Additionally, Celularity's ROCE and ROE are alarmingly low at -76.51% and -612.01%, respectively, further highlighting its financial struggles. The company's stock has underperformed significantly over the past year, down 34.10%, compared to a 10.26% gain in the S&P 500, reinforcing the notion that it is currently overvalued.